title: Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial.
abstract: BACKGROUND
  There are many drugs recommended for pain relief in patients with migraine headache.
  
  
  METHODS
  In a prospective double blind randomized clinical trial, 90 patients (age ≥ 18) presenting to Emergency medicine Department with Migraine headache were enrolled in two equal groups. We used intravenous propofol (10 mg every 5-10 minutes to a maximum of 80 mg, slowly) and intravenous dexamethasone (0.15 mg/kg to a maximum of 16 mg, slowly), in group I and II, respectively. Pain explained by patients, based on VAS (Visual Analogue Scale) was recorded at the time of entrance to ED, and after injection. Data were analyzed by paired samples t test, using SPSS 16. P < 0.05 was considered to be statistically significant.
  
  
  RESULTS
  The mean of reported pain (VAS) was 8 ± 1.52 in propofol group and 8.11 ± 1.31 in dexamethasone group at presenting time (P > 0.05). The VAS in propofol group was obviously decreased to 3.08 ± 1.7, 1.87 ± 1.28 and 1.44 ± 1.63 after 10, 20 and 30 minutes of drug injection, respectively. The VAS in dexamethasone group was 5.13 ± 1.47, 3.73 ± 1.81 and 3.06 ± 2 after 10, 20 and 30 minutes of drug injection, respectively. The mean of reported VAS in propofol group was less than dexamethasone group at the above mentioned times (P < 0.05). The reduction of headache in propofol group, also, was very faster than dexamethasone group (P < 0.05). There were no adverse side effects due to administration of both drugs.
  
  
  CONCLUSIONS
  Intravenous propofol is an efficacious and safe treatment for patients presenting with Migraine headache to the emergency department.
  
  
  BACKGROUND
  Clinical Trials IRCT201008122496N4.
authors.affiliation: Emergency Medicine Department, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz 51664, I,R, IRAN. soleimanpourh@tbzmed.ac.ir
authors.forename: Hassan
authors.initials: H
authors.lastname: Soleimanpour
authors.forename: Rouzbeh Rajaei
authors.initials: RR
authors.lastname: Ghafouri
authors.forename: Aliakbar
authors.initials: A
authors.lastname: Taheraghdam
authors.forename: Dawood
authors.initials: D
authors.lastname: Aghamohammadi
authors.forename: Sohrab
authors.initials: S
authors.lastname: Negargar
authors.forename: Samad E J
authors.initials: SE
authors.lastname: Golzari
authors.forename: Mohsen
authors.initials: M
authors.lastname: Abbasnezhad
mesh_terms: D000328:Adult; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008881:Migraine Disorders / Q000175:diagnosis* / Q000188:drug therapy*; D010147:Pain Measurement / Q000187:drug effects*; D015742:Propofol / Q000008:administration & dosage*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D018686:Anesthetics, Intravenous; D000893:Anti-Inflammatory Agents; D003907:Dexamethasone; D015742:Propofol